Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

11.0K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
11.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.2K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.2K
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

303
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
303
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K
Pharmacovigilance01:19

Pharmacovigilance

1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

242
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
242

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological factors and Cesarean section in Australian women with epilepsy.

Epilepsy & behavior : E&B·2022
Same author

Trends in Australian dental prescribing of antibiotics: 2005-2016.

Australian dental journal·2021
Same author

Antimicrobial stewardship in the primary care setting: from dream to reality?

BMC family practice·2020
Same author

Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia.

Climacteric : the journal of the International Menopause Society·2019
Same author

Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register.

Seizure·2018
Same author

Antiepileptic drug polytherapy in pregnant women with epilepsy.

Acta neurologica Scandinavica·2018
Same journal

Editorial.

Acta neurologica Scandinavica·2022
Same journal

Advances in sudden unexpected death in epilepsy.

Acta neurologica Scandinavica·2022
Same journal

Non-convulsive seizures and non-convulsive status epilepticus in neuro-intensive care unit.

Acta neurologica Scandinavica·2022
Same journal

Positron emission tomography in autoimmune encephalitis: Clinical implications and future directions.

Acta neurologica Scandinavica·2022
Same journal

Seizure detection based on wearable devices: A review of device, mechanism, and algorithm.

Acta neurologica Scandinavica·2022
Same journal

Walking confidence and perceived locomotion ability explain participation after stroke: A cross-sectional experimental study.

Acta neurologica Scandinavica·2022
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K

Triptan use in Australia 1997-2015: A pharmacoepidemiological study.

B L K D Eyre1, M J Eadie2, M L van Driel2

  • 1School of Pharmacy, The University of Queensland, Woolloongabba, Qld, Australia.

Acta Neurologica Scandinavica
|January 18, 2017
PubMed
Summary
This summary is machine-generated.

Triptan use in Australia significantly increased from 1997 to 2015, with newer medications replacing older ones. This trend suggests current migraine treatments may be insufficient.

Keywords:
Australiaacutemigrainepharmacoepidemiologytreatmenttriptans

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Related Experiment Videos

Last Updated: Mar 8, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.5K

Area of Science:

  • Pharmacology
  • Neurology
  • Public Health

Background:

  • Triptan derivatives are crucial for acute migraine treatment.
  • Understanding Australian triptan usage patterns provides insights into migraine management.

Purpose of the Study:

  • To analyze triptan derivative utilization in Australia from 1997 to 2015.
  • To compare Australian triptan use with international data.

Main Methods:

  • Utilized national drug reimbursement data for triptan prescriptions.
  • Measured dispensed use as defined daily doses (DDD) per 1000 population per day.
  • Focused on Australia's concessional beneficiaries.

Main Results:

  • Overall triptan use surged by 112% annually.
  • Sumatriptan remained dominant, with a 45% annual increase.
  • Newer triptans (rizatriptan, eletriptan) showed rapid adoption post-2010.

Conclusions:

  • Australian triptan use escalated significantly over 18 years.
  • Newer triptans successfully replaced declining use of older ones.
  • The increasing trend suggests suboptimal outcomes with current migraine therapies.